Evidence map›Paper›PMID 33614398›Full record

ReviewCurrent clinical microbiology reports2021

COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development.

Sabhiya Majid, Mosin S Khan, Samia Rashid, Ayesha Niyaz, Rabia Farooq, Showkat A Bhat, Hilal A Wani, Waseem Qureshi

Open access · bronzeAbstract readReview
In one paragraph

Review in Current clinical microbiology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Quantum dots against SARS-CoV-2: diagnostic and therapeutic potentials.Journal of chemical technology and biotechnology (Oxford, Oxfordshire : 1986) · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Sabhiya MajidDepartment of Biochemistry, Government Medical College Srinagar and Associated SMHS and Super Speciality Hospital and Research Centre, University of Kashmir Srinagar, Srinagar, J&K 190010 India.ORCID 0000-0002-3678-3313
Mosin S KhanDepartment of Biochemistry, Government Medical College Srinagar and Associated SMHS and Super Speciality Hospital and Research Centre, University of Kashmir Srinagar, Srinagar, J&K 190010 India.
Samia RashidDepartment of Medicine, Government Medical College Srinagar and Associated SMHS and Super Speciality Hospital, Srinagar, J&K 190010 India.
Ayesha NiyazSHKM Government Medical College, Mewat, Haryana India.
Rabia FarooqDepartment of Basic Medical Sciences, College of Medicine, University of Bisha, Bisha, 67714 Saudi Arabia.
Showkat A BhatDepartment of Biochemistry, Government Medical College Doda, Doda, J&K 182202 India.
Hilal A WaniDepartment of Higher Education, Government of Jammu & Kashmir, Jammu, India.
Waseem QureshiRegistrar Academics, Government Medical College Srinagar, Srinagar, J&K 190010 India.
Government Medical College · INGovernment Medical College · INUniversity of Kashmir · INUniversity of Bisha · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewHuman race is currently facing the wrath of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly transmittable and pathogenic RNA virus, causing coronavirus disease 2019 (COVID-19), the worst ever global pandemic. Coronaviruses (CoVs) have emerged as a major public health concern. Urgent global response to COVID-19 outbreak has been to limit spread of SARS-CoV-2 via extensive monitoring and containment. Various treatment regimens have been adopted to manage COVID-19, with known drugs and drug combinations used to decrease the morbidity and mortality associated with COVID-19. Intensive research on various fronts including studying molecular and structural aspects of these viruses and unraveling the pathophysiology and mechanistic basis of COVID-19 aimed at developing effective prophylactic, therapeutic agents and vaccines has been carried out globally. RECENT

findingsNo approved antiviral treatment except remdesivir exists for SARS-CoV-2 till date though novel drug targets have been identified. However, worldwide frantic and competitive vaccine development pharmaceutical race has borne fruit in the form of a number of promising candidate vaccines, out of which few have already received emergency use authorization by regulatory bodies in record time. SUMMARY: This review highlights the painstaking efforts of healthcare workers and scientific community to successfully address the COVID-19 pandemic-though damage in the form of severe illness, loss of lives, and livelihood has left a serious mark. Focusing on extensive research on various therapeutic options and antiviral strategies including neutralizing antibodies, potential drugs, and drug targets, light has been shed on various diagnostic options and the amazing vaccine development process as well.

Indexed as

CoronavirusesCOVID-19RT-PCRSARS-CoV-2Vaccines

Identifiers

PMID33614398
PMCPMC7883962
OpenAlexW3129206268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.